miR-125b's ability to fine-tune the subtle balance of apoptosis vs. cell-cycle regulators and thus buffer the p53 network dosage in different contexts, could explain why miR-125b dysregulation can lead to either tumor suppression or oncogenesis depending on the context. The gene discussed is TP53; the disease is neoplasm.